Acute Myeloid Leukemia is one of the most common types of leukemia in adults, with an incidence of 20,000 per year in the US. The proliferation of white blood cells can affect other blood cells. Red blood cells play a role in transporting oxygen to body tissues. Disruptions in the production of red blood cells can impact the clinical condition experienced by patients. Hemoglobin levels can decrease when there are disruptions in red blood cell production. Methods: This systematic review is aiming to know the abnormalities in hemoglobin levels in AML patients. The PRISMA flow diagram was used to select the literature to be reviewed. The study was conducted on a population of patients diagnosed with AML using an observational research design. AML patients with secondary diseases and those who had undergone therapy were excluded. A total of three literatures meeting the inclusion and exclusion criteria were selected for review in this study. The quality of the literature was then assessed using the JBI critical appraisal tools to minimize the risk of bias. Literature search was done using Pubmed, DOAJ, and ScienceDirect, with Acute Leukemia, Acute Myeloid Leukemia, Hematological Parameters, and Hemoglobin as the keywords. Results: A total of three literatures were obtained and analyzed. These three studies shows outcomes with low hemoglobin levels. The results obtained by Suchismita et al., 2023, indicate an average hemoglobin value of 7.2 ± 2.0 g/dL. Sanchez et al., 2015, reported a median hemoglobin value of 7.7 (5.6-12.5) g/dL. Meanwhile, Merdin et al., 2020, reported a median hemoglobin value of 8.9 g/dL. Conclusion: This systematic review shows that AML patients has a lower levels of hemoglobin than normal, with moderate to severe anemia. Further research is needed to identify the risk factors causing low hemoglobin levels in AML patients.